Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections (PKTOXDAP)

Civil Hospices of Lyon

Status: Unknown

Conditions: Bone and Joint Infection; Dactinomycin Adverse Reaction

Treatments: Other: patients having had BJI or PJI treated with daptomycin

Study type: Observational

Funder types: Other

Identifiers

NCT04933344

397

Details and patient eligibility

About

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Full description

Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013.

Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.

Enrollment: 1,130 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed

Exclusion criteria

• Patients who objected to participating in the study
• Absence of blood dosage of daptomycin

Trial design

1,130 participants in 1 patient group

patients having had BJI or PJI treated with daptomycin

Description:

patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK

Treatment:

Other: patients having had BJI or PJI treated with daptomycin